Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (4 ops.)
Latest filing published 02 Oct 2026 for NewAmsterdam Pharma Co N.V.. Read the official filing
Filing timeline
BuySaleJohannes Jacob Pieter Kastelein
Insider track record
Disclosed buys
0
Disclosed sells
4
Signal history
Johannes Jacob Pieter Kastelein: trading record in brief
This profile gathers the share dealings of Johannes Jacob Pieter Kastelein in NewAmsterdam Pharma Co N.V. Between 26 March 2024 and 30 September 2026, the trades on record add up to 10 filings.
Every open-market trade on record is a sale: 4 sales worth €2.8M. Outside the open market, there are 2 share grants and 4 option exercises. 2026 to date brings no purchases and 3 sales.
The latest filing, published on 2 October 2026, reports an option exercise in NewAmsterdam Pharma Co N.V. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Johannes Jacob Pieter Kastelein
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations10 total
50,246 sharesOrdinary SharesSEC:0001193125-26-412431:0
50,246 shares@ US$25.030.043% mcap40.1% of flowOrdinary SharesSEC:0001193125-26-412431:1
104,467 sharesOrdinary SharesSEC:0001193125-26-099073:0
14,692 shares@ US$35.0026.4% of flowOrdinary SharesSEC:0001193125-26-067260:0
6,000 shares@ US$33.2510.3% of flowOrdinary SharesSEC:0001193125-26-006662:0
50,000 shares@ US$24.2963.3% of flowOrdinary SharesSEC:0000950170-25-111241:0
19,302 shares0Ordinary SharesSEC:0000950170-25-046947:0
150,000 sharesOrdinary SharesSEC:0000950170-25-045283:0
34,000 sharesOrdinary SharesSEC:0000950170-25-003018:0
201,673 sharesOrdinary SharesSEC:0000950170-24-037241:0
10 of 10 declarations
